T0901317 CAS NO.293754-55-9

T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively, inhibits nuclear factor/κB (NF/κB) target: LXR, FXR; IC 50: 50 nM and 5 μM. In vitro: upregulates the expression and activity of TM, T0901317 treatment inhibits nuclear factor κB (NF/κB) signaling and the secretion of high glucose induced proinflammatory mediators, including tumor necrosis factor α and interleukin 1β in GECs.  T0901317 enhances the interaction between LXR α and the transcriptional coactivator, p300, in GEC extracts.  In vivo: The reference dose is 10mg/kg/d. You can dilute the product in 0.5% carboxymethylcellulose. Administration of T0901317 does not lead to severe myocardial lipid accumulation in rats despite of its high plasma availability.  Administration of T0901317 to high-fat fed rats augments diet-induced hyperlipidemia. T0901317 completely restores glucose transporter 4 expression and insulin-stimulats Akt substrate of 160 kDa phosphorylation in all investigated muscles